2024年1月25日,浙江大学医学院附属第一医院骨髓移植中心施继敏教授团队在《Cell Transplantation》杂志在线发表论文"Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients With Acute Myeloid Leukemia Harboring KMT2A ...
【翻译】(原始细胞)不表达胞浆髓过氧化物酶,也没有其他髓系和T细胞系标志的表达。 We also noticed the expression of NG2 commonly associated with KMT2A rearrangement in B-ALL. 【翻译】我们还注意到原始细胞表达神经-胶质抗原2,...
The additional cytogenetic and molecular diagnostics, revealing a KMT2A rearrangement, was decisive for the confirmation of AML. Conclusion. This case highlights the challenges of diagnosing KMT2A‐rearranged monocytic AML and the importance of careful morphological assessment in partnership...
研究结果显示,该研究达到了主要终点,在KMT2A重排的AML/ALL人群(n=57)中,可评估患者的完全缓解(CR)/部分血液学恢复(CRh)率为23%(95%CI,12.7%-35.8%;单侧P=.0036)。此外,总反应率(ORR)为63%,39%的反应者(n=14/36)进行了造血干细胞移植。 第二阶段的其他数据显示,成人患者的CR/CRh率为23%(95%CI,11...
3. A study of DSP-5336 in relapsed/refractory AML/ ALL with or without MLL rearrangement or NPM1 mutation. ClinicalTrials.gov. Updated January 18, 2024. Accessed July 15, 2024.
(7+3) and venetoclax (Venclexta) plus azacitidine (Vidaza) was found to have acceptable tolerability with preliminary evidence of clinical activity in patients with NPM1-mutant and KMT2A-rearranged acute myeloid leukemia (AML), according to early data ...
Mixed lineage leukemia [MLL; now known as lysine methyltransferase 2A (KMT2A)] rearrangement-positive acute myeloid leukemia (AML) and juvenile myelomonocytic leukemia (JMML) are distinct diseases, although age of susceptibility (infancy or early childhood) and abnormal monocytosis are common clinical ...
Pediatric acute myeloid leukemia (AML) with KMT2A rearrangement is detected in 15-20% of all pediatric AML patients and is associated with adverse outcomes even after allogeneic hematopoietic stem cell transplantation (HSCT). To investigate outcomes and prognostic factors, we investigated 90 pediatric ...
The exception is the most common KMT2A(MLL) rearrangement t(9;11)/MLLT3-KMT2A(MLL), which is associated with intermediate risk disease [9,32–34]. Not all KMT2A(MLL) translocations are detected by conventional karyotyping, in which cases FISH analysis is useful [35]. AML with t(6;9)...
In this portion of the trial, 24 patients with AML and KMT2A rearrangement or NPM1 mutation were randomly assigned to either 200 or 600 mg of ziftomenib (KMT2A rearrangement: 200 mg given to 9 patients, 600 mg given to 3 patients; NPM1 mutation: 200 mg...